{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:46:50Z","timestamp":1785026810966,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ShanghaiTech Startup funding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Carborane is considered a three-dimensional mimetic of phenyl rings in medicinal chemistry. BMS-202 is a potent PD-L1 inhibitor that can block the PD-L1\/PD-1 interaction and restore the immune response to cancer cells. Herein, we replaced the terminal phenyl group of BMS-202 with carborane and prepared its carboranyl BMS-202 analogues. The results showed a loss of PD-L1 binding affinity due to the bulky size of carborane, suggesting that carborane cannot serve as a phenyl ring mimetic in certain cases. Docking study demonstrated that the narrow binding pocket of PD-L1 could not hold the bulky carborane, resulting in loss of its activity. Compounds 1a and 1b exhibited anti-proliferative activities on a broad scope of cancer cell lines. Further studies indicate that compound 1a can induce cell apoptosis and lead to G1 cell cycle phase arrest. The boron biodistribution study of compound 1a revealed that the brain\/blood uptake ratio was 0.60 \u00b1 0.08, exhibiting a good blood-brain penetration capability.<\/jats:p>","DOI":"10.3390\/molecules30244789","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:46:52Z","timestamp":1765874812000},"page":"4789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synthesis and Anti-Tumor Evaluation of Carboranyl BMS-202 Analogues\u2014A Case of Carborane Not as Phenyl Ring Mimetic"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9164-6671","authenticated-orcid":false,"given":"Changxian","family":"Yuan","sequence":"first","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"},{"name":"College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanxiang","family":"Hao","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjing","family":"Li","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"},{"name":"Shanghai Clinical Research and Trial Center, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China"},{"name":"Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"},{"name":"School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiezheng","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-6995","authenticated-orcid":false,"given":"Zhiguang","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"},{"name":"Shanghai Clinical Research and Trial Center, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6282-1408","authenticated-orcid":false,"given":"Sinan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0010-8545(02)00087-5","article-title":"The medicinal chemistry of carboranes","volume":"232","author":"Valliant","year":"2002","journal-title":"Coord. Chem. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1039\/D2CS00024E","article-title":"Functionalization of o-carboranes via carboryne intermediates","volume":"51","author":"Qiu","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"215795","DOI":"10.1016\/j.ccr.2024.215795","article-title":"Novel promising boron agents for boron neutron capture therapy: Current status and outlook on the future","volume":"511","author":"Xu","year":"2024","journal-title":"Coord. Chem. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/cells12101398","article-title":"Next-generation boron drugs and rational translational studies driving the revival of BNCT","volume":"12","author":"Seneviratne","year":"2023","journal-title":"Cells"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.3390\/pharmaceutics15122663","article-title":"Amino acid-based boron carriers in boron neutron capture therapy (BNCT)","volume":"15","author":"Pulkkinen","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"213139","DOI":"10.1016\/j.ccr.2019.213139","article-title":"Boron agents for neutron capture therapy","volume":"405","author":"Hu","year":"2020","journal-title":"Coord. Chem. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14335","DOI":"10.1002\/chem.202002963","article-title":"Bimodal therapeutic agents against glioblastoma, one of the most lethal forms of cancer","volume":"26","author":"Couto","year":"2020","journal-title":"Chem. Eur. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1021\/acs.molpharmaceut.3c00152","article-title":"A potential boron neutron capture therapy agent selectively suppresses high-grade glioma: In vitro and in vivo exploration","volume":"20","author":"Nievas","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1039\/C9CS00197B","article-title":"New keys for old locks: Carborane-containing drugs as platforms for mechanism-based therapies","volume":"48","author":"Stockmann","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/BF01976129","article-title":"Unusually strong lipophilicity of \u2018fat\u2019 or \u2018super\u2019 amino-acids, including a new reference value for glycine","volume":"36","author":"Do","year":"1980","journal-title":"Experientia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/cphc.200500648","article-title":"Interaction of carboranes with biomolecules: Formation of dihydrogen bonds","volume":"7","author":"Horinek","year":"2006","journal-title":"ChemPhysChem"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1021\/jm990125i","article-title":"Synthesis of 5-(carboranylalkylmercapto)-2\u2032-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2","volume":"42","author":"Lunato","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41570-022-00400-x","article-title":"Carboranes in drug discovery, chemical biology and molecular imaging","volume":"6","author":"Marfavi","year":"2022","journal-title":"Nat. Rev. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1021\/cr200038x","article-title":"Carbaboranes as pharmacophores: Properties, synthesis, and application strategies","volume":"111","author":"Scholz","year":"2011","journal-title":"Chem. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Alam\u00f3n, C., D\u00e1vila, B., Garc\u00eda, M.F., S\u00e1nchez, C., Kovacs, M., Trias, E., Barbeito, L., Gabay, M., Zeineh, N., and Gavish, M. (2020). Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-\u03b2, exhibits powerful in Vivo anti-glioblastoma activity. Cancers, 12.","DOI":"10.3390\/cancers12113423"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Couto, M., Alam\u00f3n, C., Garc\u00eda, M.F., Kovacs, M., Trias, E., Nievas, S., Pozzi, E., Curotto, P., Thorp, S., and Dagrosa, M.A. (2020). Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-decorated lapatinib-scaffold for cancer therapy combining tyrosine kinase inhibition and boron neutron capture therapy. Cells, 9.","DOI":"10.3390\/cells9061408"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1002\/chem.201705181","article-title":"Discovery of potent EGFR inhibitors through the incorporation of a 3D-aromatic-boron-rich-cluster into the 4-anilinoquinazoline scaffold: Potential drugs for glioma treatment","volume":"24","author":"Couto","year":"2018","journal-title":"Chem. Eur. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1021\/acs.jmedchem.1c01215","article-title":"Bioisosteres of the phenyl ring: Recent strategic applications in lead optimization and drug design","volume":"64","author":"Subbaiah","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1039\/D5CC00816F","article-title":"Recent advances in bridged structures as 3D bioisosteres of ortho-phenyl rings in medicinal chemistry applications","volume":"61","author":"Xia","year":"2025","journal-title":"Chem. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"114483","DOI":"10.1016\/j.ejmech.2022.114483","article-title":"Ring replacement recommender: Ring modifications for improving biological activity","volume":"238","author":"Ertl","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1016\/j.bmcl.2006.05.032","article-title":"m-Carborane bisphenol structure as a pharmacophore for selective estrogen receptor modulators","volume":"16","author":"Ogawa","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20933","DOI":"10.1021\/ja208797n","article-title":"Boron cluster-based development of potent nonsecosteroidal vitamin D receptor ligands: Direct observation of hydrophobic interaction between protein surface and carborane","volume":"133","author":"Fujii","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9396","DOI":"10.1021\/jacs.0c02228","article-title":"Too persistent to give up: Aromaticity in boron clusters survives radical structural changes","volume":"142","author":"Poater","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1021\/jm300094u","article-title":"Application of the bicyclo [1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active \u03b3-secretase inhibitor","volume":"55","author":"Stepan","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.omto.2022.01.005","article-title":"Carboranes as unique pharmacophores in antitumor medicinal chemistry","volume":"24","author":"Chen","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1002\/chem.201700209","article-title":"Carboranes as aryl mimetics in catalysis: A highly active zwitterionic NHC-precatalyst","volume":"23","author":"Selg","year":"2017","journal-title":"Chem. Eur. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cmdc.200900072","article-title":"Asborin: The carbaborane analogue of aspirin","volume":"4","author":"Scholz","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.ejmech.2011.01.030","article-title":"Carbaboranes as pharmacophores: Similarities and differences between aspirin and asborin","volume":"46","author":"Scholz","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.3390\/molecules26102843","article-title":"Modulation of \u03b3-secretase activity by a carborane-based flurbiprofen analogue","volume":"26","author":"Saretz","year":"2021","journal-title":"Molecules"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cmdc.201500199","article-title":"nido-Dicarbaborate induces potent and selective inhibition of cyclooxygenase-2","volume":"11","author":"Neumann","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_31","unstructured":"(2015). Compounds Useful as Immunomodulators (Standard No. WO 2015\/034820 A1)."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"30323","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)","volume":"7","author":"Zak","year":"2016","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41467-021-21410-1","article-title":"Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1","volume":"12","author":"Park","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1021\/acs.jmedchem.2c01801","article-title":"Novel small-molecule PD-L1 inhibitor induces PD-L1 internalization and optimizes the immune microenvironment","volume":"66","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-molecule inhibitors of the programmed cell death-1\/programmed death-ligand 1 (PD-1\/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1","volume":"60","author":"Guzik","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1021\/acs.jmedchem.9b00795","article-title":"Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1\/programmed death-ligand 1 protein\u2013protein interaction","volume":"62","author":"Basu","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1021\/acs.jmedchem.1c01682","article-title":"Discovery of small-molecule inhibitors of the PD-1\/PD-L1 axis that promote PD-L1 internalization and degradation","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"130155","DOI":"10.1016\/j.bmcl.2025.130155","article-title":"Discovery and biological evaluation of carborane-containing derivatives as TEAD auto palmitoylation inhibitors","volume":"121","author":"Li","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_40","first-page":"18720","article-title":"Synthesis and anticancer activity evaluation of novel carborane-containing isoflavonoid analogues","volume":"10","author":"Zhang","year":"2025","journal-title":"ACS Omega"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1021\/acs.molpharmaceut.9b00464","article-title":"Synthesis and initial biological evaluation of boron-containing prostate-specific membrane antigen ligands for treatment of prostate cancer using boron neutron capture therapy","volume":"16","author":"Wang","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1021\/ic400928v","article-title":"High yielding preparation of dicarba-closo-dodecaboranes using a silver(I) mediated dehydrogenative alkyne-insertion reaction","volume":"52","author":"Toppino","year":"2013","journal-title":"Inorg. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e202424072","DOI":"10.1002\/anie.202424072","article-title":"Ortho-carborane-derived halogen bonding organocatalysts","volume":"64","author":"Vonnemann","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1002\/anie.201311012","article-title":"High yielding synthesis of carboranes under mild reaction conditions using a homogeneous silver(I) catalyst: Direct evidence of a bimetallic intermediate","volume":"53","author":"Keskar","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"12036","DOI":"10.1021\/acsomega.9b01142","article-title":"Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method","volume":"4","author":"Cai","year":"2019","journal-title":"ACS Omega"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.5012\/bkcs.2013.34.4.1051","article-title":"Facile docking and scoring studies of carborane ligands with estrogen receptor","volume":"34","author":"Ok","year":"2013","journal-title":"Bull. Korean Chem. Soc."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Donarska, B., Cytarska, J., Ko\u0142odziej-Sobczak, D., Studzinska, R., Kupczyk, D., Baranowska-\u0141aczkowska, A., Jaroch, K., Szeliska, P., Bojko, B., and R\u00f3zycka, D. (2024). Synthesis of carborane\u2013thiazole conjugates as tyrosinase and 11\u03b2-hydroxysteroid dehydrogenase inhibitors: Antiproliferative activity and molecular docking studies. Molecules, 29.","DOI":"10.3390\/molecules29194716"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/24\/4789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:47:29Z","timestamp":1765874849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/24\/4789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":47,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["molecules30244789"],"URL":"https:\/\/doi.org\/10.3390\/molecules30244789","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}